TARA Protara Therapeutics, Inc.
company
SEC Filings & Insider Trading Activity 2026

CIK: 1359931
Health Care
Biological Products, (No Diagnostic Substances) 52 filings
Russell 2000

Latest Protara Therapeutics, Inc. (TARA) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 10, 2026, a 10-Q quarterly report filed on November 10, 2025, an 8-K current report filed on March 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Protara Therapeutics, Inc. (TARA) (SEC CIK 1359931), with AI-powered section-by-section summaries updated daily.

10-Q: 34
10-K: 12
8-K: 6

Latest 2026 SEC Filing Dates

10-K Annual Report
Mar 10, 2026
10-Q Quarterly Report
Nov 10, 2025
8-K Current Report
Mar 30, 2026

AI 8-K Current Report Analysis
Recent 8-K Filings

Filed Mar 10, 2026
8-K
Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Protara Therapeutics (TARA) filed earnings results via Exhibit 99.1 press release — full financials contained in that exhibit
  • Furnished (not "filed") under SEC rules, meaning no Section 18 liability — standard practice for earnings releases
Filed Feb 24, 2026
8-K
Full analysis →

Item 7.01: Regulation FD Disclosure

  • Standard Reg FD "furnished not filed" disclaimer — no investor-actionable content disclosed in this section

Item 8.01: Other Events

  • BCG-Unresponsive cohort: 65.7% CR at any time; 68.2% CR at 6 months; 100% of 12-month responders maintained CR through month 12
  • BCG-Naïve cohort: stronger durability — 72.4% CR at any time; 57.9% CR at 12 months; 100% (11/11) maintained CR from months 9–12

Recent 8-K Filings
Current Reports

AI-powered analysis of Protara Therapeutics, Inc. (TARA) 8-K current reports disclosing material events.

Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4

FormFiling DatePeriodAnalysisSEC
8-K
Mar 30, 2026
8-K
Mar 10, 2026Analysis
10-K
Mar 10, 2026Dec 31, 2025
8-K
Feb 24, 2026Analysis
8-K
Dec 15, 2025
8-K
Dec 8, 2025
8-K
Dec 3, 2025
10-Q
Nov 10, 2025Sep 30, 2025
10-Q
Aug 11, 2025Jun 30, 2025
10-Q
May 8, 2025Mar 31, 2025
10-K
Mar 5, 2025Dec 31, 2024
10-Q
Nov 12, 2024Sep 30, 2024
10-Q
Aug 6, 2024Jun 30, 2024
10-Q
May 2, 2024Mar 31, 2024
10-K
Mar 13, 2024Dec 31, 2023
10-Q
Nov 3, 2023Sep 30, 2023
10-Q
Aug 3, 2023Jun 30, 2023
10-Q
May 4, 2023Mar 31, 2023
10-K
Mar 8, 2023Dec 31, 2022
10-Q
Nov 3, 2022Sep 30, 2022
10-Q
Aug 9, 2022Jun 30, 2022
10-Q
May 5, 2022Mar 31, 2022
10-K
Mar 9, 2022Dec 31, 2021
10-Q
Nov 4, 2021Sep 30, 2021
10-Q
Aug 5, 2021Jun 30, 2021

Frequently Asked Questions

What are the latest TARA SEC filings in 2026?

Protara Therapeutics, Inc. (TARA) has filed a 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 10, 2025, an 8-K current report on March 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did TARA file its most recent 10-K annual report?

Protara Therapeutics, Inc. (TARA) filed its most recent 10-K annual report on March 10, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view TARA 10-Q quarterly reports?

Protara Therapeutics, Inc. (TARA)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every TARA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has TARA filed recently?

Protara Therapeutics, Inc. (TARA)'s most recent 8-K was filed on March 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find TARA insider trading activity (Form 4)?

SignalX aggregates every TARA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does TARA file with the SEC?

Protara Therapeutics, Inc. (TARA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TARA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Protara Therapeutics, Inc. (TARA).

What is TARA's SEC CIK number?

Protara Therapeutics, Inc. (TARA)'s SEC CIK (Central Index Key) number is 1359931. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1359931 to look up all TARA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find TARA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Protara Therapeutics, Inc. (TARA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.

Stay on top of Protara Therapeutics, Inc. SEC filings

Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 52+ filings.